Abstract
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a Hodgkin lymphoma expressing functional B-cell receptors (BCR). Recently, we described a dual stimulation model of IgD+ lymphocyte-predominant cells by Moraxella catarrhalis antigen RpoC and its superantigen MID/hag, associated with extralong CDR3 and HLA-DRB1*04 or HLADRB1* 07 haplotype. The aim of the present study was to extend the antigen screening to further bacteria and viruses. The fragment antibody-binding (Fab) regions of seven new and 15 previously reported cases were analyzed. The reactivity of non-Moraxella spp.-reactive Fab regions against lysates of Rothia mucilaginosa was observed in 5/22 (22.7%) cases. Galactofuranosyl transferase (Gltf) and 2,3-butanediol dehydrogenase (Bdh) of R. mucilaginosa were identified by comparative silver- and immuno-staining in two-dimensional gels, with subsequent mass spectrometry and validation by western blots and enzyme-linked immunosorbent assay. Both R. mucilaginosa Gltf and Bdh induced BCR pathway activation and proliferation in vitro. Apoptosis was induced by recombinant Gltf/ETA’-immunotoxin conjugates in DEV cells expressing recombinant R. mucilaginosa-reactive BCR. Reactivity against M. catarrhalis RpoC was confirmed in 3/7 newly expressed BCR (total 10/22 reactive to Moraxella spp.), resulting in 15/22 (68.2%) cases with BCR reactivity against defined bacterial antigens. These findings strengthen the hypothesis of bacterial trigger contributing to subsets of NLPHL.
Introduction
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) accounts for 5-16% of Hodgkin lymphomas.1 The disease-defining lymphocyte-predominant (LP) tumor cells have a late germinal center B-cell phenotype. NLPHL variants with a diffuse growth pattern and histiocyte-rich microenvironment are closely related to T-cell/histiocyterich large B-cell lymphoma (THRLBCL).2,3 When NLPHL was first described, a frequently indolent course was noted and a potential misguided immune response to infection was speculated.4 In contrast to Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma, LP cells are usually negative for Epstein-Barr virus and have a preserved B-cell phenotype, including B-cell receptor (BCR) expression.5 NLPHL is genotypically distinct from classical Hodgkin lymphoma, with frequent BCL6 translocations and recurrent mutations in SGK1, DUSP2 and JUNB.2,6-11 The intraclonal immunoglobulin variable (IgV) region gene diversification,8 strong expression of BCL612 and AID,13,14 and a histological picture that resembles a germinal center suggest an ongoing immune response.15 In the recently published classification of the International Consensus Conference NLPHL was renamed to nodular lymphocyte predominant B-cell lymphoma (NLPBL),16 but in the simultaneously published current 5th version of the World Health Organization classification the term NLPHL was retained.17 Activation of the nuclear factor (NF)-κB pathway is observed in LP cells;2 however, NF-κB activity in LP cells is not caused by mutations in NFKBIA or TNFAIP318 or by latent Epstein-Barr virus5 infection. It may therefore represent a consequence of chronic BCR stimulation. In line with this hypothesis, we demonstrated that dynamic immunological synapses are formed between LP cells and the surrounding rosetting follicular T helper (TFH) cells.19 IgD+ NLPHL had been reported to have a strong male predominance and to present primarily with cervical manifestations.20 We reported the reactivities of mostly IgD+ LP cells against the specific antigens of Moraxella spp. associated with a specific IGVH genotype, a presumably permissive HLA class II haplotype (HLA-DRB01*04 or HLA-DRB01*07), and the presence of light chain-restricted serum antibodies against M. catarrhalis RpoC. Moreover, we proposed a BCR co-stimulation model of IgD+ LP cells by M. catarrhalis RpoC via the fragment antibody-binding (Fab) region and the IgD-binding superantigen MID/hag via the Fc domain.21,22 In another study, similar immunoglobulin genes were found in nonIgD+ NLPHL cases.23 Having identified M. catarrhalis as a trigger for a subset of NLPHL, we hypothesized that there may be further, possibly commensal bacteria eliciting NLPHL. The aim of the present study was, therefore, to extend the screening of the recombinant Fab regions of LP cells to other microbial antigens, particularly those that are part of the resident flora of the oral cavity, upper respiratory tract and gut, such as Rothia spp, Enterococcus spp., and Lactobacillus spp. A second aim of the study was to confirm the reactivity against M. catarrhalis RpoC by analysis of new cases.
Methods
Study samples
The study was approved by the institutional review boards of the University Cancer Center (UCT), the Ethics Committee at the University Hospital Frankfurt (project number: SHN-06-2018), and the local ethics committee of the Ärztekammer des Saarlandes, Saarbrücken (Ha 147/17). Frozen tissue sections of NLPHL specimens were obtained from the Department of Pathology of the UCT Frankfurt, Tampere University, Tampere, Finland, from the Institute of Pathology, CHUV Lausanne, Switzerland, and from the Department of Pathology, Uppsala University Hospital, Sweden. All NLPHL cases were negative for Epstein-Barr virus. Informed consent was obtained from the patients in accordance with the Declaration of Helsinki. The sera of patients with classical Hodgkin lymphoma or NLPHL were obtained from the HD13 (ISRCTN63474366), HD14 (ISRCTN04761296), HD15 (ISRCTN32443041), HD16 (NCT00736320), HD17 (NCT01356680), and HD18 (NCT00515554) trials of the German Hodgkin Study Group.24-27 Sera from patients with THRLBCL were obtained from the RICOVER (NCT00052936), Hi-CHOEP (NCT00129090), UNFOLDER (NCT00278408), FLYER (NCT00278421), and CHOP-R-ESC (NCT00290667) trials, and sera from patients with primary mediastinal B-cell lymphoma were obtained from the UNFOLDER (NCT00278408) trial of the German High-Grade Non-Hodgkin Lymphoma Study Group.28-31
Fab region screening in bacterial lysates and virome array
Laser microdissection of LP cells from cryospecimens and IgV gene multiplex seminested polymerase chain reactions were performed, as described by Küppers et al.32 This also applies to the prokaryotic expression cloning of the recombinant Fab regions in Escherichia coli TG1 (Online Supplementary Methods).33-35
To screen for the potential reactivity of Fab regions against bacterial antigens, heat-inactivated lysates of different bacterial strains or patients’ isolates, including Rothia aeria and Rothia mucilaginosa, were provided by the Institute of Medical Microbiology and Hygiene of Saarland University, Homburg/Saar, Germany (Online Supplementary Methods).
To verify the specificity of the reactivities of NLPHL-derived Fab regions against the components of R. mucilaginosa, recombinant Fab regions derived from primary central nervous system lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, primary mediastinal B-cell lymphoma and chronic lymphocytic leukemia were screened against these recombinant FLAG-tagged antigens of R. mucilaginosa by enzyme-linked immunosorbent assay.35-37
In addition, the recombinant NLPHL-Fab regions were screened on a custom-made VIROME microarray representing 2,206 viral genes chosen from 158 viruses (ASU, Biodesign Institute, Arizona State University, AZ, USA) (Online Supplementary Methods).
Generation of DEV cells expressing Rothia spp.-reactive B-cell receptors followed by activation, proliferation, and apoptosis assays afer stimulation with Rothia antigens and immunotoxins
DEV cells expressing Rothia-reactive BCR were generated as previously described (Online Supplementary Methods).20,22 DEV cells either expressing a BCR with reactivity against Rothia mucilaginosa Gltf or Moraxella catarrhalis RpoC, and of IgD or IgG class, were subjected to western blot for activation of the BCR pathway, proliferation and apoptosis assays after stimulation with the respective bacterial antigens or incubation with bacterial antigens conjugated with an immunotoxin (Online Supplementary Methods).
HLA genotyping
HLA-DRB1 and HLA-DQ typing was performed for all patients via sequencing (Labor Thiele, Kaiserslautern, Germany).
Statistical analysis
Normality was evaluated using the Shapiro-Wilk and Kolmogorov-Smirnov tests. Statistical significance was calculated using unpaired, two-tailed t tests for comparison of parametric distributions, without adaptation for multiple comparisons (Prism 9, GraphPad).
Results
Patient, HLA-DRB1, and IgV gene characteristics
The previous expression-cloned cohort of the Fab regions of 15 NLPHL cases21,22 was extended by Ig heavy and light chain gene amplification from microdissected LP cells with an additional seven NLPHL cases (Table 1; IgV gene characteristics are presented in Table 2). The median age of the patients with successfully amplified rearranged IgV genes was 28 (9-65) years, with a male predominance (18/22, 82%). IgD+ LP cells were identified in 11 patients with a median age of 21 (12–42) years (male:female 9:2).
Table 1.Characteristics of the patients with nodular lymphocyte-predominant Hodgkin lymphoma included in this study
B-cell receptors derived from lymphocyte-predominant cells react with lysates of M. catarrhalis and R. mucilaginosa
Three of seven of the new recombinant Fab regions bound to lysates of Moraxella spp. In combination with seven Moraxella-reactive Fab regions from the first 15 cases, 10/22 cases were Moraxella spp.-reactive, and nine of them were derived from IgD+ positive cases (Figure 1A).
In contrast, the pooled NLPHL Fab regions reacted in dotblots against lysates of R. mucilaginosa. Following individual testing of these Fab regions, 5/22 NLPHL-derived BCR (#2, #12, #15, #16 and #19, with 1/5 IgD+) reacted against R. mucilaginosa lysates (Figure 1A). None of these five Fab regions cross-reacted with M. catarrhalis lysates. In western blots of R. mucilaginosa lysates using the NLPHL-derived Fab regions as primary antibodies, two bands of approximately 35-40 kDa and 75 kDa were detected (Figure 1B; Online Supplementary Figures S3 and S4).
Following two-dimensional gel-based isolation of single spots (Figure 1C), mass spectrometry was used to identify glycerol-3-phopshate dehydrogenase/oxidase (WP_44150604), Gtf)/Gltf (WP_012903226), type I glyceraldehyde-3-phosphate dehydrogenase (WP_012903599), 1-deoxy-D-xylulose-5-phosphate synthase (WP_044150996), 2-oxoglutarate dehydrogenase, E2 component, dihydrolipoamide succinyltransferase (WP_044150317), 2,3-butanediol dehydrogenase (WP_044150456), and iron-sulfur cluster-binding protein (WP_012902908) of R. mucilaginosa as probable candidate antigens.
Specific binding of the R. mucilaginosa-reactive recombinant BCR in the R. mucilaginosa lysate against recombinant Gltf as the antigen or band/spot of 75 kDa and against Bdh as the antigen or band/spot of 39 kDa was verified by enzymelinked immunosorbent assay (Figure 1D).
Table 2.IgV heavy chain gene analysis of lymphocyte-predominant cells and identified antigenic targets.
In contrast to NLPHL, none of the recombinant BCR derived from primary central nervous system lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia cases reacted with the R. mucilaginosa lysate (Online Supplementary Figure S3). Furthermore, no Fab reactivity was detected against the total R. mucilaginosa lysate or against any of the other investigated bacteria.
Virome screening of the pooled non-Moraxella spp.-reactive Fab regions resulted in 13 candidate antigens with normalized values ≥2: CbCD00959563 of coxsackievirus B1, MsCD00595052 of measles, strain Ichinose WT, CagA_884_2.1, and CagA_FL_2.1 of Helicobacter pylori 26695, HrCD00959476 of human rhinovirus A1, HsCD00959820 and HsCD00959751 of H1N1 subtype, CbCD00594880 of coxsackievirus B4 (strain E2), CaCD00959834 of coxsackievirus A9, HrCD00956402 of human rubulavirus 2, HcCD00959896 of human coronavirus NL63, and HsCD00959755 of H3N2 subtype (Online Supplementary Table S3; Online Supplementary Figure S1). After expression cloning of the obtained plasmids, non-reactivity against these candidate antigens was confirmed on dot-plots with the pooled NLPHL Fab regions (data not shown).
Figure 1.Reactivity of recombinant IgD+ lymphocyte-predominant cell-derived Fab regions with bacterial lysates. (A) Representative immuno-dot blots of bacterial lysates, showing reactivity against lysate of M. catarrhalis from previously reported Fab regions, and from Fab regions of new cases as validation. In addition there are nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)-derived recombinant Fab regions of five cases (#2, #12, #15, #16, #19) bound to lysates of R. mucilaginosa. (B) Representative western blot of polyacrylamide gel electrophoresis of lysate of R. mucilaginosa using pooled and individual recombinant Fab regions of NLPHL, which had shown reactivity against R. mucilaginosa as primary antibody. Two bands of approximately 35-40 kDa and 75 kDa were detected. (C) Silver staining of lysate of R. mucilaginosa for 45 min of blotting gel (Proteome factory AG, Berlin, Germany), and immunostain of antigens as dots in a two-dimensional gel blot using the recombinant pooled NLPHL Fab region as primary antibody. (D) Enzyme-linked immunosorbent assay with recombinant C-terminally FLAG-tagged potential antigens of R. mucilaginosa identified by mass spectrometry. The respective Fab region at a concentration of 10 μg/mL (positive control = rec. the Fab region of patient #11) showed a reactivity against galactofuranosyl transferase and 2,3-butanediol dehydrogenase of R. mucilaginosa.
Serum antibodies against galactofuranosyl transferase and 2,3-butanediol dehydrogenase of R. mucilaginosa in patients with nodular lymphocyte-predominant Hodgkin lymphoma
Antibodies with relevant titers against R. mucilaginosa Gltf were found in 2/98 (2%) and against R. mucilaginosa Bdh in 3/98 (3%) of patients with NLPHL enrolled in the clinical trials of the German Hodgkin Study Group (Figure 2A), which is representative of the general population of NLPHL patients. All antibodies against R. mucilaginosa Gltf and Bdh were of IgG class and predominantly of the IgG1 subclass, and they were kappa light-chain restricted (Figure 2C, D). The titers ranged from 1:400 to 1:800 (Figure 2B). No patient with classical Hodgkin lymphoma (0/98) (Figure 2A), THRLBCL (0/50), or primary mediastinal B-cell lymphoma (0/80) (Online Supplementary Figure S4) presented serum antibodies against Gltf and Bdh of R. mucilaginosa. In summary, antibodies against Gltf and Bdh of R. mucilaginosa were found in NLPHL patients but not in patients with related lymphomas.-
Figure 2.Serological responses against Gltf and Bdh of R. mucilaginosa. (A) Sera of patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and classical Hodgkin lymphoma (cHL) (diluted 1:100) were tested for antibodies against galactofuranosyl transferase (Gltf) and 2,3-butanediol dehydrogenase (Bdh) of R. mucilaginosa. (B) Titers of anti-Gltf antibodies and anti-2,3-Bdh antibodies in seropositive patients with NLPHL (left) or cHL (right). The curves represent the optical density (OD) at 490 nm of different serum dilutions. Patients with NLPHL had titers between 1:200 and 1:800. (C) Analysis of Ig classes, and IgG subclasses of serum-antibodies against Gltf and 2,3-Bdh of R. mucilaginosa in patients with NLPHL. The antiGltf antibodies and anti-2,3-Bdh antibodies were exclusively of the IgG class, mostly IgG1. (D) Light chains of serum-antibodies against Gltf and 2,3-Bdh of R. mucilaginosa in patients with NLPHL.
R. mucilaginosa galactofuranosyl transferase induces stimulation of lymphocyte-predominant cells
Because we hypothesized that specific stimulation of the LP-cell BCR by R. mucilaginosa Gltf contributes to lymphomagenesis in a subset of NLPHL, we functionally investigated patient-derived Gltf-specific BCR. For this purpose, cells of the only available NLPHL cell line (DEV) were transfected to express, in a doxycycline-dependent manner, recombinant BCR derived from patients #2 and #3 with constant regions Cγ or Cδ.
Gltf stimulation resulted in strong activation of the BCR signaling pathway in DEV cells that stably expressed Gltf-reactive BCR, as determined by phosphorylation of key BCR signaling factors (pTyr525/526 spleen tyrosine kinase [SYK], pTyr96 B-cell linker [BLNK], pTyr759 phosphoinositide-specific phospholipase C [PLC]γ2, and pTyr223 Bruton tyrosine kinase [BTK]) (Figure 3A). Activation of the BCR pathway was associated with a significant increase in MYC expression (Figure 3A).
Stimulation with recombinant R. mucilaginosa Gltf resulted in significantly increased proliferation of DEV cells that stably expressed Gltf-reactive BCR (Figure 3B). Furthermore, the recombinant immuno-conjugate of R. mucilaginosa Gltf conjugated to a truncated form of the exotoxin A of Pseudomonas aeruginosa (Gltf/ETA’) inhibited proliferation of DEV cells stably expressing Gltfspecific BCR but had no effect on non-transfected DEV cells or on DEV cells that expressed M. catarrhalis RpoC-reactive BCR (Figure 3B). An increase in the number of apoptotic cells was detected via annexin V/propidium iodide staining after incubation with R. mucilaginosa Gltf/ETA’ in the DEV cells expressing a recombinant BCR with the respective reactivity, but not in DEV cells with different reactivity of recombinant BCR - i.e. against M. catarrhalis RpoC - or without doxycycline induction of recombinant BCR at all (Figure 3C).
Figure 3.Stimulation of different types of lymphocyte-predominant cells by Gltf of R. mucilaginosa. (A) Activation of the B-cell receptor (BCR) signaling pathway. Western blot analysis of components of the BCR signaling pathway shows activation by R. mucilaginosa galactofuranosyl transferase (Gltf) and by M. catarrhalis RpoC in DEV cells transfected and expressing R. mucilaginosa-Gltf-reactive recombinant BCR of case #2 with stronger bands of the activated isoforms pTyr525/526 SYK, pTyr96 BLNK, pTyr759 PLCγ2 and pTyr223 BTK and of MYC after incubation with R. mucilaginosa Gltf. Similarly, reaction to the BCR pathway after incubation with M. catarrhalis RpoC to DEV cells with RpoC-reactive BCR of case #3. (B) Tetrazolium proliferation assay with the transfected DEV cells expressing recombinant nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)-derived BCR with reactivity against Gltf of R. mucilaginosa or RpoC of M. catarrhalis. Stimulation with Gltf of R. mucilaginosa increased proliferation in DEV cells transfected to express Gltf-reactive BCR but not in DEV cells expressing RpoC-reactive BCR. Incubation by ETA’ toxin-conjugated to Gltf of R. mucilaginosa or to RpoC/ETA’ of M. catarrhalis on DEV cells expressing either recombinant NLPHL-derived BCR (#2) with reactivity against R. mucilaginosa Gltf or against M. catarrhalis RpoC-reactive (#3) led to a decrease in proliferation. *P<0.05; **P≤0.01, ***P≤0.001, ****P≤0.0001. (C) Apoptosis induced by ETA’ toxin-conjugated to Gltf of R. mucilaginosa or RpoC of M. catarrhalis is dependent on doxycycline-induced expression of Gltf- or RpoC-reactive BCR on lymphocyte-predominant cells. Characterization of DEV cells transfected to express doxycycline-inducible IgD+ recombinant BCR with (from case #2) reactivity against Gltf of R. mucilaginosa or RpoC of M. catarrhalis (from case #3) by annexin-V/FITC and propidium iodide staining after 24 h culture in the presence of RpoC/ETA’, Gltf/ETA’ or staurosporin. Dox: doxycycline.
Discussion
The present study strengthens the evidence for the contribution of chronic antigenic simulation by common bacteria to subsets of NLPHL.38 Two specific antigens of R. mucilaginosa were identified as targets for BCR in 5/22 NLPHL cases. In addition, the reactivity against M. catarrhalis RpoC antigens was verified for recombinant BCR from 3/7 newly analyzed NLPHL cases, resulting in a total reactivity of 10/22 cases against Moraxella spp. In addition to R. mucilaginosa, the recombinant lymphoma BCR of most cases (15/22; 68.2%) were reactive against specific bacterial antigens.
As seen before for M. catarrhalis RpoC, light chain-restricted antibodies against R. mucilaginosa Gltf and 2,3-Bdh, predominantly of the IgG1 subclass, were observed in NLPHL sera. While serum antibodies for M. catarrhalis RpoC were relatively frequently identified in NLPHL patients, antibodies against R. mucilaginosa were less frequently observed. Both light chain-restricted antibodies against Rpoc and R. mucilaginosa are probably the result of a very strong immune reaction against the specific antigen. However, not all patients with such lymphoma BCR reactivity have high titers of serum antibodies; this discrepancy was also seen for lymphoma BCR reactivity against Ars2 in ABC-type diffuse large B-cell lymphoma and for LRPAP1 in mantle cell lymphoma.39-41 Similar to previous observations of M. catarrhalis RpoC,22 no antibodies against R. mucilaginosa Gltf or Bdh were detected in the sera of patients with THRLBCL, the NLPHL-related aggressive B-cell lymphoma subtype,42,43 suggesting a distinct mechanism in these lymphomas. R. mucilaginosa is a commensal, Gram-positive, coagulase-negative coccus and a part of the resident flora of the oral cavity. It typically resides in the anatomical drainage area of cervical lymph nodes.44 However, in immunocompromised patients, R. mucilaginosa can be pathogenic, and bacteremia can occur.38,39,41-44
Regarding the previously described association of ultralong CDR3 with reactivity against M. catarrhalis RpoC, the extended cohort of NLPHL Fab regions revealed that reactivity against M. catarrhalis RpoC was not restricted to BCR with ultralong CDR3, and some cases with ultralong CDR3 were reactive to antigens of R. mucilaginosa. Therefore, ultralong CDR3 and skewed IGHD-IGHJ usage are likely not specific to reactivity against a specific antigen but instead represent a relatively frequent structural combination, suggesting that LP cells frequently stem from a B-cell population with ultralong CDR3 that regularly exists in healthy individuals. Recently, in a VH3-23 model of natural antibodies, Wang et al. described skewed usage of IGHD2-IGHJ6 and IGHD3-IGHJ6 rearrangements connected to the presence of ultralong CDR3 loops that stabilized the long CDR3 loop rather than contributing to the paratop.20,45
The clustering of HLA-DRB1:04 and DRB1:07 haplotypes in Moraxella-reactive NLPHL22 suggests cognate T-cell involvement in the immune reaction that finally leads to lymphoma development. Further studies demonstrated the formation of immunological synapses between TFH and LP cells, which further supports this idea.19 No HLA restriction was observed in NLPHL cases with R. mucilaginosa-directed BCR, with the limitation of a low number of cases. In addition to the lower pathogenicity compared with M. catarrhalis, R. mucilaginosa is not known to express a superantigen like MID/hag of M. catarrhalis.46-48 Considering its potential as a chronic antigenic trigger, it should be noted that R. mucilaginosa is known to form biofilms. In vitro, both R. mucilaginosa Gltf and Bdh induced growth by activating the BCR pathway.
A main limitation of the study is that our selection of viral and bacterial pathogens represents only a fraction of the environmental pathogens; therefore, we likely did not consider all the potential variables. In the current study, we selected R. mucilaginosa and R. aeria as they occur in a pattern that is comparable to that of Moraxella spp. in oropharyngeal samples and other samples of the upper respiratory tract. This necessitates further and extended systematic screening for microbial antigens, including comprehensive microbiome banks. In addition to NLPHL, certain lymphomas, such as duodenal or pediatric follicular lymphoma, different types of marginal zone lymphomas, and more aggressive lymphomas should be studied in this context. The findings lead to the question of why and under which circumstances immune responses against common bacteria - even a component of the oral resident flora -trigger lymphoma.46-48 From the present study it is difficult to conclude how far bacterial antigens actively support growth of NLPHL once the lymphoma has developed and how far this may be targetable by antibiotic treatment. As eradication of the infectious trigger has been proven successful and has even become standard therapy for some advanced indolent lymphoma entities,49-53 this might serve as a therapeutic model to be investigated in future clinical trials. However, heterogeneity of LP cells, their active somatic hypermutation of BCR genes, and also transformation into high-grade lymphomas would represent challenges for an antibiotic-based therapeutic approach. On the other hand, the rarity of NLPHL poses a serious challenge to the feasibility of a meaningful clinical trial. Possible proposals for clinical trials might initially investigate the relapsed, advanced setting with an exclusive low-grade manifestation and detection of corresponding antibodies against M. catarrhalis or R. mucilaginosa.
Given recent reports from retrospective analyses regarding less intensive treatments and active surveillance strategies for NLPHL,54 the results of the present study should stimulate discussions on clinical trials investigating antibiotic therapy or vaccination strategies against bacteria-associated NLPHL subgroups.
Footnotes
- Received January 23, 2023
- Accepted April 24, 2023
Correspondence
Disclosures
LT has received travel grants from Abbvie, Janssen and EUSA-Pharm, and consultancy fees from Takeda, Astra-Zeneca, Merck and EUSA-pharm (less than $10,000 each). The other authors declare no competing interests.
Contributions
LT, SLB, and SH designed the study, performed experiments, analyzed data and wrote the manuscript. NF, ER, KL, FN, and NS performed experiments and analyzed data. SR, JB, YJK, RMB, AN, MV, CS, LdL, PB, AE, VP, and GH supplied essential material and interpreted data. RK, ET, KDP, SMH, OC, IAK, ES, MH, MLH, and MB designed the study, interpreted data, and revised the manuscript.
Data-sharing statement
All relevant data are available in the Article and Online Supplementary Information or from the corresponding author upon reasonable request.
Funding
MP, LT, K-DP, and FN have been supported by the Wilhelm Sander Stiftung. LT was supported by a University of Saarland fellowship and by the NanoBioMed young investigator program of Saarland University. SH is supported by the Deutsche Forschungsgemeinschaft (grant HA 6145/7-1).
Acknowledgments
We thank Claudia Schormann and the DSHNHL team and Bernhard Thurner for constant support, advice, and critical reading of the manuscript.
References
- Saarinen S, Pukkala E, Vahteristo P, Mäkinen MJ, Franssila K, Aaltonen LA. High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2013; 31(7):938-943. https://doi.org/10.1200/JCO.2012.43.5958|PubMed|Google Scholar
- Brune V, Tiacci E, Pfeil I. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008; 205(10):2251-2268. https://doi.org/10.1084/jem.20080809|PubMed|PubMed Central|Google Scholar
- Hartmann S, Doring C, Jakobus C. Nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease?. PLoS One. 2013; 8(11):e78812. Google Scholar
- Jackson H, Parker F., Hodgkin’s disease. II. Pathology. N Engl J Med. 1944; 231:35-44. https://doi.org/10.1056/NEJM194407132310201|Google Scholar
- Anagnostopoulos I, Hansmann ML, Franssila K. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000; 96(5):1889-1899. Google Scholar
- Hartmann S, Schuhmacher B, Rausch T. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia. 2015; 40(9):2278-2285. https://doi.org/10.1038/leu.2015.328|PubMed|Google Scholar
- Kuppers R, Rajewsky K, Braeuninger A, Hansmann ML. L&H cells in lymphocyte-predominant Hodgkin’s disease. N Engl J Med. 1998; 338(11):763-764. https://doi.org/10.1056/NEJM199803123381113|PubMed|Google Scholar
- Marafioti T, Hummel M, Anagnostopoulos I. Origin of nodular lymphocyte-predominant Hodgkin’s disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997; 337(7):453-458. https://doi.org/10.1056/NEJM199708143370703|PubMed|Google Scholar
- Wlodarska I, Nooyen P, Maes B. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood. 2003; 101(2):706-710. https://doi.org/10.1182/blood-2002-05-1592|PubMed|Google Scholar
- Mottok A, Renné C, Willenbrock K, Hansmann ML, Bräuninger A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood. 2007; 110(9):3387-3390. https://doi.org/10.1182/blood-2007-03-082511|PubMed|Google Scholar
- Braeuninger A, Kuppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A. 1997; 94(17):9337-9342. https://doi.org/10.1073/pnas.94.17.9337|PubMed|PubMed Central|Google Scholar
- Falini B, Bigerna B, Pasqualucci L. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin’s disease. Blood. 1996; 87(2):465-471. https://doi.org/10.1182/blood.V87.2.465.bloodjournal872465|Google Scholar
- Greiner A, Tobollik S, Buettner M. Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma. J Pathol. 2005; 205(5):541-547. https://doi.org/10.1002/path.1746|PubMed|Google Scholar
- Muramatsu M, Sankaranand VS, Anant S. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem. 1999; 274(26):18470-18476. https://doi.org/10.1074/jbc.274.26.18470|PubMed|Google Scholar
- Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003; 27(10):1346-1356. https://doi.org/10.1097/00000478-200310000-00007|PubMed|Google Scholar
- Campo E, Jaffe ES, Cook JR. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140(11):1229-1253. https://doi.org/10.1182/blood.2022015851|PubMed|PubMed Central|Google Scholar
- Alaggio R, Amador C, Anagnostopoulos I. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. https://doi.org/10.1038/s41375-022-01625-x|PubMed|PubMed Central|Google Scholar
- Schumacher MA, Schmitz R, Brune V. Mutations in the genes coding for the NF-kappaB regulating factors IkappaBalpha and A20 are uncommon in nodular lymphocytepredominant Hodgkin’s lymphoma. Haematologica. 2010; 95(1):153-157. https://doi.org/10.3324/haematol.2009.010157|PubMed|PubMed Central|Google Scholar
- Bein J, Thurner L, Hansmann ML, Hartmann S. Lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma interact with rosetting T cells in an immunological synapse. Am J Hematol. 2020; 95(12):1495-1502. https://doi.org/10.1002/ajh.25972|PubMed|Google Scholar
- Prakash S, Fountaine T, Raffeld M, Jaffe ES, Pittaluga S. IgD positive L&H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol. 2006; 30(5):585-592. https://doi.org/10.1097/01.pas.0000194741.87798.45|PubMed|Google Scholar
- Thurner L, Kemele M, Regitz E. Moraxella catarrhalis-a bacterial involvement in the origin of nodular lymphocyte predominant Hodgkin lymphoma of IGD type?. Haematologica. 2015; 100(s1):106-107. Google Scholar
- Thurner L, Hartmann S, Fadle N. Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma. Nat Commun. 2020; 11(1):2465. https://doi.org/10.1038/s41467-020-16375-6|PubMed|PubMed Central|Google Scholar
- Paschold L, Willscher E, Bein J. Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation. Haematologica. 2021; 106(10):2654-2666. https://doi.org/10.3324/haematol.2021.278427|PubMed|PubMed Central|Google Scholar
- Behringer K, Goergen H, Hitz F. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015; 385(9976):1418-1427. https://doi.org/10.1016/S0140-6736(14)61469-0|PubMed|Google Scholar
- Engert A, Borchmann P, Pluetschow A. Dose-escalation with BEACOPP escalated is superior to ABVD in the combinedmodality treatment of early unfavorable Hodgkin lymphoma: final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010; 116(21):765. https://doi.org/10.1182/blood.V116.21.765.765|Google Scholar
- Borchmann P, Goergen H, Kobe C. EBEACOPP with or without rituximab in interim-PET-positive advanced-stage Hodgkin lymphoma: updated results of the international, randomized phase 3 GHSG HD18 trial. Hematol Oncol. 2017; 35(S2):65. https://doi.org/10.1002/hon.2437_52|Google Scholar
- Borchmann P, Goergen H, Kobe C. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017; 390(10114):2790-2802. https://doi.org/10.1016/S0140-6736(17)32134-7|PubMed|Google Scholar
- Pfreundschuh M, Schubert J, Ziepert M. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008; 9(2):105-116. https://doi.org/10.1016/S1470-2045(08)70002-0|PubMed|Google Scholar
- Schmitz N, Nickelsen M, Ziepert M. Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). J Clin Oncol. 2011; 29(15_suppl):8002. https://doi.org/10.1200/jco.2011.29.15_suppl.8002|Google Scholar
- Pfreundschuh M, Murawski N, Ziepert M. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. J Clin Oncol. 2018; 36(15_suppl):7574. https://doi.org/10.1200/JCO.2018.36.15_suppl.7574|Google Scholar
- Poeschel V, Held G, Ziepert M. Excellent outcome of young patients (18-60 years) with favourable-prognosis diffuse large B-cell lymphoma (DLBCL) treated with 4 cycles CHOP plus 6 applications of rituximab: results of the 592 patients of the Flyer trial of the DSHNHL/GLA. Blood. 2018; 132(Suppl 1):781. https://doi.org/10.1182/blood-2018-99-112403|Google Scholar
- Kuppers R, Schneider M, Hansmann ML. Laser-based microdissection of single cells from tissue sections and PCR analysis of rearranged immunoglobulin genes from isolated normal and malignant human B cells. Methods Mol Biol. 2013; 971:49-63. https://doi.org/10.1007/978-1-62703-269-8_3|PubMed|Google Scholar
- Voswinkel J, Kerkdijk AJ, Mueller A, Assmann G, Pfreundschuh M, Held G. A novel system to test for specificity of B cell receptors from tissue of Wegener’s granulomatosis patients. Clin Exp Rheumatol. 2008; 26(3 Suppl 49):S90-S96. Google Scholar
- de Haard HJ, van NN Reurs A. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem. 1999; 274(26):18218-18230. https://doi.org/10.1074/jbc.274.26.18218|PubMed|Google Scholar
- Zwick C, Fadle N, Regitz E. Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells. Blood. 2013; 121(23):4708-4717. https://doi.org/10.1182/blood-2012-08-447904|PubMed|Google Scholar
- Thurner L, Nimmesgern A, Neumann F. LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting. Leukemia. 2019; 33(1):148-158. Google Scholar
- Thurner L, Preuss K-D, Bewarder M. Hyper N-glycosylated SAMD14 and neurabin-I as driver CNS autoantigens of PCNSL. Blood. 2018; 132(26):2744-2753. https://doi.org/10.1182/blood-2018-03-836932|PubMed|Google Scholar
- Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005; 5(4):251-262. https://doi.org/10.1038/nrc1589|PubMed|Google Scholar
- Thurner L, Hartmann S, Bewarder M. Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma. Haematologica. 2021; 106(8):2224-2232. https://doi.org/10.3324/haematol.2019.241653|PubMed|PubMed Central|Google Scholar
- Thurner L, Hartmann S, Fadle N. LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting. Leukemia. 2019; 33(1):148-158. https://doi.org/10.1038/s41375-018-0182-1|PubMed|Google Scholar
- Thurner L, Fadle N, Bittenbring JT. LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. Blood. 2021; 137(23):3251-3258. https://doi.org/10.1182/blood.2020008835|PubMed|PubMed Central|Google Scholar
- Hartmann S, Döring C, Jakobus C. Nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma - endpoints of a spectrum of one disease?. PLoS One. 2013; 8(11):e78812. https://doi.org/10.1371/journal.pone.0078812|PubMed|PubMed Central|Google Scholar
- Hartmann S, Döring C, Vucic E. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Br J Haematol. 2015; 169(3):415-422. https://doi.org/10.1111/bjh.13310|PubMed|Google Scholar
- Masters BR. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, Eighth Edition (2015) Eds: John E. Bennett, Raphael Dolin, Martin J. Blaser. ISBN: 13-978-1-4557-4801-3, Elsevier Saunders. Graefes Arch Clin Exp Ophthalmol. 2016; 254:2285-2287. https://doi.org/10.1007/s00417-015-2950-1|Google Scholar
- Wang H, Yan K, Wang R. Antibody heavy chain CDR3 length-dependent usage of human IGHJ4 and IGHJ6 germline genes. Antib Ther. 2021; 4(2):101-108. https://doi.org/10.1093/abt/tbab010|PubMed|PubMed Central|Google Scholar
- Forsgren A, Grubb AO. Many bacterial species bind human IgD. J Immunol. 1979; 122(4):1468-1472. https://doi.org/10.4049/jimmunol.122.4.1468|Google Scholar
- Perez Vidakovics ML, Riesbeck K. Virulence mechanisms of Moraxella in the pathogenesis of infection. Curr Opin Infect Dis. 2009; 22(3):279-285. https://doi.org/10.1097/QCO.0b013e3283298e4e|PubMed|Google Scholar
- Samuelsson M, Jendholm J, Amisten S, Morrison SL, Forsgren A, Riesbeck K. The IgD CH1 region contains the binding site for the human respiratory pathogen Moraxella catarrhalis IgD-binding protein MID. Eur J Immunol. 2006; 36(9):2525-2534. https://doi.org/10.1002/eji.200535594|PubMed|Google Scholar
- Zucca E, Arcaini L, Buske C. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(1):17-29. https://doi.org/10.1016/j.annonc.2019.10.010|PubMed|Google Scholar
- Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991; 338(8776):1175-1176. https://doi.org/10.1016/0140-6736(91)92035-Z|PubMed|Google Scholar
- Wotherspoon AC, Doglioni C, Diss TC. Regression of primary low-grade B-cell gastric lymphoma of mucosaassociated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993; 342(8871):575-577. https://doi.org/10.1016/0140-6736(93)91409-F|PubMed|Google Scholar
- Chanudet E, Zhou Y, Bacon CM. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol. 2006; 209(3):344-351. https://doi.org/10.1002/path.1984|PubMed|Google Scholar
- Ferreri AJM, Govi S, Pasini E. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012; 30(24):2988-2994. https://doi.org/10.1200/JCO.2011.41.4466|PubMed|Google Scholar
- Borchmann S, Joffe E, Moskowitz CH. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019; 133(20):2121-2129. https://doi.org/10.1182/blood-2018-10-877761|PubMed|PubMed Central|Google Scholar
Data Supplements
Figures & Tables
Table 1.Characteristics of the patients with nodular lymphocyte-predominant Hodgkin lymphoma included in this study
Table 2.IgV heavy chain gene analysis of lymphocyte-predominant cells and identified antigenic targets.
Figure 1.Reactivity of recombinant IgD+ lymphocyte-predominant cell-derived Fab regions with bacterial lysates. (A) Representative immuno-dot blots of bacterial lysates, showing reactivity against lysate of M. catarrhalis from previously reported Fab regions, and from Fab regions of new cases as validation. In addition there are nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)-derived recombinant Fab regions of five cases (#2, #12, #15, #16, #19) bound to lysates of R. mucilaginosa. (B) Representative western blot of polyacrylamide gel electrophoresis of lysate of R. mucilaginosa using pooled and individual recombinant Fab regions of NLPHL, which had shown reactivity against R. mucilaginosa as primary antibody. Two bands of approximately 35-40 kDa and 75 kDa were detected. (C) Silver staining of lysate of R. mucilaginosa for 45 min of blotting gel (Proteome factory AG, Berlin, Germany), and immunostain of antigens as dots in a two-dimensional gel blot using the recombinant pooled NLPHL Fab region as primary antibody. (D) Enzyme-linked immunosorbent assay with recombinant C-terminally FLAG-tagged potential antigens of R. mucilaginosa identified by mass spectrometry. The respective Fab region at a concentration of 10 μg/mL (positive control = rec. the Fab region of patient #11) showed a reactivity against galactofuranosyl transferase and 2,3-butanediol dehydrogenase of R. mucilaginosa.
Figure 2.Serological responses against Gltf and Bdh of R. mucilaginosa. (A) Sera of patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and classical Hodgkin lymphoma (cHL) (diluted 1:100) were tested for antibodies against galactofuranosyl transferase (Gltf) and 2,3-butanediol dehydrogenase (Bdh) of R. mucilaginosa. (B) Titers of anti-Gltf antibodies and anti-2,3-Bdh antibodies in seropositive patients with NLPHL (left) or cHL (right). The curves represent the optical density (OD) at 490 nm of different serum dilutions. Patients with NLPHL had titers between 1:200 and 1:800. (C) Analysis of Ig classes, and IgG subclasses of serum-antibodies against Gltf and 2,3-Bdh of R. mucilaginosa in patients with NLPHL. The antiGltf antibodies and anti-2,3-Bdh antibodies were exclusively of the IgG class, mostly IgG1. (D) Light chains of serum-antibodies against Gltf and 2,3-Bdh of R. mucilaginosa in patients with NLPHL.
Figure 3.Stimulation of different types of lymphocyte-predominant cells by Gltf of R. mucilaginosa. (A) Activation of the B-cell receptor (BCR) signaling pathway. Western blot analysis of components of the BCR signaling pathway shows activation by R. mucilaginosa galactofuranosyl transferase (Gltf) and by M. catarrhalis RpoC in DEV cells transfected and expressing R. mucilaginosa-Gltf-reactive recombinant BCR of case #2 with stronger bands of the activated isoforms pTyr525/526 SYK, pTyr96 BLNK, pTyr759 PLCγ2 and pTyr223 BTK and of MYC after incubation with R. mucilaginosa Gltf. Similarly, reaction to the BCR pathway after incubation with M. catarrhalis RpoC to DEV cells with RpoC-reactive BCR of case #3. (B) Tetrazolium proliferation assay with the transfected DEV cells expressing recombinant nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)-derived BCR with reactivity against Gltf of R. mucilaginosa or RpoC of M. catarrhalis. Stimulation with Gltf of R. mucilaginosa increased proliferation in DEV cells transfected to express Gltf-reactive BCR but not in DEV cells expressing RpoC-reactive BCR. Incubation by ETA’ toxin-conjugated to Gltf of R. mucilaginosa or to RpoC/ETA’ of M. catarrhalis on DEV cells expressing either recombinant NLPHL-derived BCR (#2) with reactivity against R. mucilaginosa Gltf or against M. catarrhalis RpoC-reactive (#3) led to a decrease in proliferation. *P<0.05; **P≤0.01, ***P≤0.001, ****P≤0.0001. (C) Apoptosis induced by ETA’ toxin-conjugated to Gltf of R. mucilaginosa or RpoC of M. catarrhalis is dependent on doxycycline-induced expression of Gltf- or RpoC-reactive BCR on lymphocyte-predominant cells. Characterization of DEV cells transfected to express doxycycline-inducible IgD+ recombinant BCR with (from case #2) reactivity against Gltf of R. mucilaginosa or RpoC of M. catarrhalis (from case #3) by annexin-V/FITC and propidium iodide staining after 24 h culture in the presence of RpoC/ETA’, Gltf/ETA’ or staurosporin. Dox: doxycycline.
Article Information
This work is licensed under a Creative Commons Attribution 4.0 International License.